2021
DOI: 10.1007/s13555-021-00598-6
|View full text |Cite
|
Sign up to set email alerts
|

Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629

Abstract: Introduction: Pembrolizumab provided durable responses and acceptable safety in recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC) in the KEYNOTE-629 study. In this elderly, fragile population with disfiguring tumours, preservation of health-related quality of life (HRQoL) is critical. Here, we present pre-specified exploratory HRQoL anal-yses from the first interim analysis of KEYNOTE-629. Methods: Patients with R/M cSCC not amenable to surgery or radiation therapy received pembrolizumab 2… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
16
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 9 publications
(18 citation statements)
references
References 27 publications
2
16
0
Order By: Relevance
“…Possible reasons for the low HRQoL perceived by patients with NMSC are the fact that cancer usually occurs in exposed areas. Frequent surgical treatment may lead to disfigurement and a high recurrence rate of the disease, which will lead to physical, psychological, and social dysfunction (32). We found that the dimension of symptoms and feelings had the most significant impact on the HRQoL scale.…”
Section: Discussionmentioning
confidence: 75%
“…Possible reasons for the low HRQoL perceived by patients with NMSC are the fact that cancer usually occurs in exposed areas. Frequent surgical treatment may lead to disfigurement and a high recurrence rate of the disease, which will lead to physical, psychological, and social dysfunction (32). We found that the dimension of symptoms and feelings had the most significant impact on the HRQoL scale.…”
Section: Discussionmentioning
confidence: 75%
“…Hence, the health‐related quality of life is critical when CSCC patients during antitumor treatments. For locally advanced or metastatic CSCC patients treated with anti‐PD‐1 agents (cemiplimab or pembrolizumab), the clinical effects have been found to translate into the benefits validated by health‐related quality of life improvement 22,23 …”
Section: Discussionmentioning
confidence: 99%
“…The EQ-5D-5L instrument includes a descriptive system comprising five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/ depression) scored using five response levels and a visual analog scale (VAS) [19]. A detailed description of these instruments and their utility in the cSCC setting has been published previously [17].…”
Section: Methodsmentioning
confidence: 99%
“…In the phase 2 KEYNOTE-629 study, pembrolizumab demonstrated robust antitumor activity and a favorable safety profile in a relatively fragile study population composed primarily of elderly and heavily pretreated patients with LA or R/M cSCC [15,16]. Prespecified analysis of HRQoL in patients with R/M cSCC at the first interim analysis (data cutoff, 8 April 2019) showed that HRQoL was stable with pembrolizumab and that improvement in HRQoL was positively correlated with treatment response [17]. We present HRQoL results from the second interim analysis of KEYNOTE-629 (data cutoff, 29 July 2020), which represents updated results for patients with R/M cSCC and the first report of HRQoL data for patients with LA cSCC.…”
Section: Introductionmentioning
confidence: 99%